In an analysis from the Canadian Cancer Trials Group MA.32 study reported in the Journal of Clinical Oncology, Pamela Goodwin, MD, MSc, FRCPC, FASCO, and colleagues found that adjuvant metformin did not reduce the risk of new primary invasive cancers vs placebo in patients with early breast cancer. ...
In a phase Ib/II study (innovaTV 205/GOG-3024/ENGOT-cx8) reported in the Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, and colleagues found that tisotumab vedotin-tftv combined with carboplatin or pembrolizumab showed activity in both treatment-naive and previously treated patients with ...
In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodrug, to nivolumab did not improve treatment outcomes in previously untreated patients with advanced...
In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib, nivolumab, and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) showed activity as a first-line treatment regimen for patients with HER2-negative metastatic...
In an interim analysis of a small phase I study reported in The New England Journal of Medicine, Chiesa et al found that base-edited CAR7 T cells were active in pediatric patients with relapsed T-cell acute lymphoblastic leukemia (ALL). As stated by the investigators: “Cytidine deamination that is...
As reported in the Journal of Clinical Oncology by Cash et al, 10-year follow-up of the Children’s Oncology Group Study AEWS0031 has shown a maintained event-free survival benefit with interval-compressed chemotherapy vs standard-timing chemotherapy in patients with localized Ewing sarcoma....
In a phase II trial reported in The New England Journal of Medicine, Chen et al found that atezolizumab produced durable responses in patients with advanced alveolar soft-part sarcoma. As stated by the investigators: “Alveolar soft-part sarcoma is a rare soft-tissue sarcoma with a poor prognosis...
In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) was associated with improved patient-reported swallowing function vs standard IMRT in newly diagnosed patients with head and neck cancer. Study...
In a phase III study (ENGOT-EN5/GOG-3055/SIENDO) reported in the Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, and colleagues found that a progression-free survival benefit with maintenance selinexor vs placebo after first-line chemotherapy in patients with advanced or recurrent...
In a phase I/II trial (CC-92480-MM-001) reported in The New England Journal of Medicine, Paul G. Richardson, MD, and colleagues found that the combination of the novel cereblon E3 ubiquitin ligase modulator mezigdomide and dexamethasone showed activity in heavily pretreated patients with relapsed...
In the Chinese phase III NOTABLE trial reported in the Journal of Clinical Oncology, Shukui Qin, MD, and colleagues examined the addition of the EGFR inhibitor nimotuzumab to gemcitabine in patients with KRAS wild-type locally advanced or metastatic pancreatic cancer. Study Details In the...
In a Chinese study reported in The New England Journal of Medicine, Li et al found evidence that the anti–Epstein-Barr virus (EBV) anti-BNLF2b total antibody, P85-Ab, may be a promising biomarker for nasopharyngeal cancer screening. Study Details In the study, a peptide library representing highly...
In an analysis reported in the Journal of Clinical Oncology, Knikman et al found that reduced doses of fluoropyrimidine therapy in patients with cancer with DPYD variant alleles did not result in poorer outcomes vs DPYD wild-type controls receiving full fluoropyrimidine doses. Study Details The...
On July 20, 2023, quizartinib was approved for use with standard cytarabine and anthracycline induction and cytarabine consolidation and as maintenance monotherapy following consolidation chemotherapy in adults with newly diagnosed acute myeloid leukemia that is FLT3 internal tandem duplication...
On August 2, 2023, the fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, was approved for use with bevacizumab for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based...
In a phase II trial (I-SABR) reported in The Lancet, Joe Y. Chang, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the addition of immunotherapy with nivolumab to stereotactic ablative radiotherapy (SABR) improved ...
On July 31, 2023, the immune checkpoint inhibitor dostarlimab-gxly was approved by the U.S. Food and Drug Administration (FDA) for use with carboplatin and paclitaxel, followed by single-agent dostarlimab, for patients with primary advanced or recurrent endometrial cancer that is mismatch...
In a phase II study (coopERA Breast Cancer) reported in The Lancet Oncology, Sara A. Hurvitz, MD, and colleagues found that 2 weeks of the addition of neoadjuvant giredestrant—a novel nonsteroidal selective estrogen receptor (ER) degrader—to palbociclib showed a stronger antiproliferative effect...
In a single-center, phase I, first-in-human trial reported in The Lancet Oncology, Yoshie Umemura, MD, and colleagues investigated treatment with the combination of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK) and Flt3L (Ad-hCMV-Flt3L) in adults with primary high-grade glioma. As stated...
In a study reported in a research letter in JACC: CardioOncology, Hibler et al found that survivors of young adult cancers who were exposed to anthracyclines were at an increased risk of subsequent diagnosis of heart failure. Study Details The study involved electronic health record data from the...
In a phase II trial reported in the Journal of Clinical Oncology, Hargrave et al found that dabrafenib plus trametinib was highly active in pediatric patients with relapsed or refractory BRAF V600–mutant high-grade glioma. Study Details In the trial, 41 previously treated patients (median age, 13...
In a systematic review and meta-analysis reported in JAMA Oncology, Xie et al explored outcomes associated with immune checkpoint inhibition among patients with advanced hepatocellular carcinoma with Child-Pugh B vs Child-Pugh A liver function. Study Details The analysis included 22 studies...
In an analysis of the UKCTOCS study reported in The Lancet Oncology, Menon et al found that patients with high-grade serous tubo-ovarian cancer detected on multimodal screening may have a survival benefit over those whose disease was diagnosed without screening. The investigator stated, “In...
In a retrospective cohort study reported in JACC: CardioOncology, Bell et al found individuals with a diagnosis of cardiovascular disease were more likely to have a subsequent cancer diagnosis than individuals with no cardiovascular disease diagnosis. Risk was elevated among persons with...
In a study reported in the Journal of Clinical Oncology, Mandelker et al found that pancreatic acinar cell carcinoma was associated with a high prevalence of BRCA2 germline pathogenic variants and genomic features of homologous recombination deficiency (HRD). The study involved somatic and germline ...
In a genetic analysis from the Blood and Marrow Transplant Clinical Trials Network 1102 Study reported in the Journal of Clinical Oncology, Versluis et al found that allogeneic hematopoietic cell transplantation (HCT) improved overall survival compared with non-HCT treatment in patients with...
In a phase III trial (LUNAR) reported in The Lancet Oncology, Leal et al evaluated the addition of tumor treating fields therapy to standard systemic therapy in patients with metastatic non–small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. As stated by ...
In a study of SEER (Surveillance, Epidemiology, and End Results) data reported in JAMA Network Open, Stephens et al found that approximately 5% of patients with invasive breast cancer had missing components of receptor status and identified several factors associated with the lack of information....
In the phase III ATALANTE/ENGOT-ov29 trial reported in the Journal of Clinical Oncology, Kurtz et al found that the addition of atezolizumab to bevacizumab and platinum-based doublets did not significantly improve progression-free survival among patients with platinum-sensitive ovarian cancer....
In an analysis reported in a letter to the editor in The New England Journal of Medicine, Palmer et al identified evidence that polatuzumab vedotin-piiq–containing regimens were preferentially effective among patients with diffuse large B-cell lymphoma (DLBCL) with activated B cell (ABC) vs...
In a Spanish phase II study (Atezo-Brain; GECP17/05) reported in the Journal of Clinical Oncology, Ernest Nadal, MD, PhD, and colleagues investigated the activity of the combination of atezolizumab with chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) with...
In a phase I study reported in The New England Journal of Medicine, Sacher et al found that the covalent KRAS G12C inhibitor divarasib (also referred to as GDC-6036) produced durable responses in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. In the study, 137 patients ...
In a Swiss phase II study (SAKK 06/17) reported in the Journal of Clinical Oncology, Richard Cathomas, MD, and colleagues found that the addition of perioperative durvalumab to neoadjuvant chemotherapy resulted in improved event-free and overall survival in patients with muscle-invasive urothelial...
In an 8-year follow-up of a Korean phase III trial (ASTRRA) reported in the Journal of Clinical Oncology, Baek et al evaluated the effects of adding adjuvant ovarian function suppression to tamoxifen in premenopausal patients with estrogen receptor (ER)-positive breast cancer, with a focus on the...
In a phase I/II study (TRANSCEND CLL 004) reported in The Lancet, Tanya Siddiqi, MD, and colleagues found evidence of activity with the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia...
In a retrospective cohort study reported in JAMA Network Open, Goodman et al found that patients receiving adjuvant PD-1 inhibitor therapy for high-risk resected melanoma often had chronic immune-related adverse events, with some persisting over long-term follow-up. Study Details The study included ...
In a single-center retrospective study reported in the Journal of Clinical Oncology, Eskreis-Winkler et al found that contrast-enhanced magnetic resonance imaging (MRI) using a high-temporal/high-spatial resolution (HTHS) protocol improved breast cancer detection and reduced unnecessary biopsies vs ...
As reported in The New England Journal of Medicine by Ingo K. Mellinghoff, MD, FACP, and colleagues, the phase III INDIGO trial has shown that vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, significantly improved progression-free survival vs placebo in patients with ...
In a study using SEER (Surveillance, Epidemiology, and End Results) registry data reported in JAMA Network Open, Koh et al found that the incidence of cancer among individuals in the United States younger than age 50 years—defined as early-onset cancer—increased significantly between 2010 and 2019. ...
In the long-term treatment phase of an Israeli phase II study reported in the journal Nutrients, Keizman et al found that PectaSol modified citrus pectin (P-MCP) may be effective in patients with nonmetastatic, biochemically relapsed prostate cancer. As stated by the investigators, “[P-MCP] is a...
In an analysis from a phase II European trial reported in JAMA Oncology, Jens Huober, MD, and colleagues found no difference in overall survival with pertuzumab/trastuzumab, with or without chemotherapy, followed by second-line ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive...
In a study from the National Institutes of Health All of Us Research Program reported in JAMA Network Open, Shi et al found that alcohol consumption and risky drinking behaviors were common among patients with a cancer diagnosis, including patients currently receiving treatment for their cancer....
In a Chinese phase II trial (TD-FOREKNOW) reported in JAMA Oncology, Lei et al found that the addition of neoadjuvant camrelizumab to platinum-based chemotherapy resulted in a higher pathologic complete response rate among patients with resectable stage IIIA or IIIB (T3N2) non–small cell lung...
In a German prospective registry study (SenTa) reported in JAMA Surgery, Kuemmel et al found that targeted axillary dissection alone after neoadjuvant systemic therapy was associated with outcomes similar to those obtained with targeted axillary dissection plus axillary lymph node dissection in...
In a phase II trial (ROSEWOOD) reported in the Journal of Clinical Oncology, Zinzani et al found that the addition of zanubrutinib to obinutuzumab significantly improved objective response rate among patients with relapsed or refractory follicular lymphoma. Study Details In the open-label trial,...
In a phase II trial reported in the Journal of Clinical Oncology, Slovin et al found that concomitant abiraterone acetate plus prednisone (AAP) and cabazitaxel appeared to produce better outcomes than AAP followed by cabazitaxel upon disease progression in patients with metastatic...
In a Canadian study reported in the Journal of Clinical Oncology, Wilkinson et al found that breast cancer screening was associated with greater 10-year breast cancer net survival among women aged 40 to 49 living in jurisdictions including mammography screening programs for this age group, compared ...
As reported in a research letter in JAMA Oncology by Reinhard Dummer, MD, and colleagues, the final, 5-year analysis of a phase II trial showed continued improvement in outcomes with the addition of neoadjuvant talimogene laherparepvec (T-VEC) to surgery in patients with advanced melanoma. Study...
As reported in The Lancet Oncology by Özgüroğlu et al, extended follow-up of the phase III EMPOWER-Lung 1 trial has shown continued benefit in overall and progression-free survival with first-line cemiplimab-rwlc vs chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with...
In a U.S. retrospective cohort study reported in JAMA Network Open, Sebastian et al found that treatment at a high-volume radiation facility was associated with improved overall survival among men with very high–risk prostate cancer receiving curative-intent radiotherapy with androgen-deprivation...